Table 1.
Clinical characteristics of the entire group
| Entire Group (n = 607) | |
|---|---|
| Age over 65 years old, n (%) | 337 (55.5) |
| Male Sex, n (%) | 335 (55.2) |
| Steroids, n (%) | 17 (2.8) |
| Diabetes Mellitus, n (%) | 101 (16.6) |
| Alb (g/dl), Mean ± SD | 3.4 ± 0.7 |
| CRP (mg/dl), Mean ± SD | 2.2 ± 4.2 |
| Nutrition, n (%) | 170 (28.0) |
| ANC < 1500 cells/mm3, n (%) | 36 (5.9) |
| Underlying Disease | |
| Colon and Intestinal Cancer, n (%) | 169 (27.8) |
| Head and Neck Cancer, n (%) | 43 (7.1) |
| Hepatobiliary Pancreatic Cancer, n (%) | 159 (26.2) |
| Gastric Cancer, n (%) | 32 (5.3) |
| Esophageal Cancer, n (%) | 24 (4.0) |
| Breast Cancer, n (%) | 19 (3.1) |
| Gynecologic Cancer, n (%) | 67 (11.0) |
| Hematological Disease, n (%) | 29 (4.8) |
| Lung Cancer, n (%) | 20 (3.3) |
| Urothelial and Kidney Cancer, n (%) | 7 (1.2) |
| Primary Brain Tumor, n (%) | 7 (1.2) |
| Soft Tissue and Bone Malignancies, n (%) | 4 (0.7) |
| Other Benign Disease, n (%) | 27 (4.4) |
| Procedure Details | |
| Right Sided Implantation, n (%) | 560 (92.3) |
| Length of Catheter (cm), Mean ± SD | 17.3 ± 3.2 |
| Preoperative Antibiotics, n (%) | 237 (39.0) |
| TIVAP-Related Infection | |
| Infection Rate, n (%) | 37 (6.1) |
| Infection per 1000 Catheter-Days | 0.187 |
SD Standard Deviation, Alb Albumin, CRP C-reactive protein, ANC Absolute neutrophil count, TIVAP Totally implantable venous access port